TINAVI(SH:688277)2023-04-25 16:00Financial Performance - The company reported a revenue of 156.19 million yuan for the year 2022, with a net loss attributable to shareholders of 110.58 million yuan[4]. - The net profit excluding non-recurring gains and losses was a loss of 133.45 million yuan[4]. - The company has not yet achieved profitability since its listing, which was under the Shanghai Stock Exchange's Sci-Tech Innovation Board standards[4]. - The company's operating revenue for 2022 was CNY 156,188,437.41, a slight increase of 0.11% compared to CNY 156,021,920.91 in 2021[21]. - The net profit attributable to shareholders of the listed company was a loss of CNY 133,454,105.70, which represents an increase in loss of 29.25% compared to a loss of CNY 103,219,039.37 in 2021[21]. - Basic earnings per share for 2022 was a loss of CNY 0.26, which is a 36.84% increase in loss compared to a loss of CNY 0.19 in 2021[22]. - The net cash flow from operating activities for 2022 was a negative CNY 87,506,239.40, compared to a negative CNY 77,755,219.56 in 2021[21]. - The net profit for 2022 was a loss of CNY 112.34 million, an increase in loss of 35.92% year-on-year[34]. - The company reported a significant decrease in costs for supporting equipment and consumables, with a direct cost of 746.61 million, down 40.22% from the previous year's 1,249.00 million[99]. - The company will not distribute profits for the year 2022 due to negative retained earnings as of December 31, 2022[171]. Research and Development - The company increased its R&D investment to 78.52% of operating revenue, up from 70.37% in 2021, reflecting a growth of 8.15 percentage points[22]. - The company's R&D investment reached CNY 122.64 million in 2022, an increase of 11.70% year-on-year[37]. - The company submitted 90 new patent applications during the reporting period, including 37 invention patent applications[37]. - The company has established a comprehensive R&D system that includes cutting-edge technology research, advanced product pre-research, and product development, collaborating with universities, research institutions, and hospitals[46]. - The company aims to integrate new technologies such as 5G communication, 3D printing, smart materials, big data, artificial intelligence, and virtual/augmented reality into its surgical robots, enhancing their intelligence and interaction capabilities[50]. - The company has developed high-precision online calibration technology for its surgical robots, ensuring positioning errors within 0.5 mm, which is critical for surgical safety and accuracy[52]. - The company has created algorithms for multi-modal medical image preprocessing and fusion, allowing for pixel-level precision in integrating preoperative and intraoperative images[54]. - The company employs artificial intelligence algorithms for automatic feature recognition in medical imaging, achieving an error of less than 1 pixel, which enhances surgical accuracy and efficiency[55]. - The company has developed a modular design technology for surgical tools, allowing the orthopedic surgical robot to adapt to various surgical requirements and expand its operational capabilities[57]. - The company has completed the iterative development of three generations of orthopedic surgical robots, enhancing clinical advantages such as precision and minimally invasive procedures[75]. Market and Competition - The orthopedic surgical robot market is still in its early clinical application phase, with increasing awareness among hospitals, doctors, and patients[4]. - The company aims to expand its market share and accelerate the implementation of application scenarios while focusing on technological innovation[4]. - The company is positioned as a leading player in the domestic orthopedic surgical robot market, with increasing competition from new entrants in the industry[49]. - The market for surgical robots is expected to expand rapidly, with a growing recognition and acceptance among doctors and patients, leading to a broader customer base beyond first and second-tier cities[50]. - The company is experiencing intensified competition from major multinational medical device companies, which may threaten its market share and profitability[84]. Operational Efficiency - Sales expenses rose by CNY 19,979,000, a year-on-year increase of 27.97%, due to increased market investment and marketing team development[23]. - The company has implemented a diversified revenue structure, transitioning from single device sales to include ongoing medical technology service income[43]. - The company has established a collaborative innovation mechanism in the medical robotics field, enhancing its continuous innovation capabilities[37]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder interests[136]. - The company has effectively managed its subsidiaries, improving overall operational efficiency and risk resistance[177]. Employee and Management - The company has a total of 362 employees, with 104 holding doctoral or master's degrees, and 128 dedicated to research and development, representing 35.36% of the workforce[78]. - The average salary of R&D personnel rose to 57.54 million, compared to 54.37 million in the previous year[74]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 198.37 million RMB[152]. - The total remuneration for core technical personnel at the end of the reporting period was 95.31 million RMB[153]. - The company has a strict compensation policy based on annual operating performance and industry income levels, ensuring competitive salaries[168]. - The management team emphasizes performance-based remuneration linked to financial and operational metrics[152]. Strategic Initiatives - The company plans to continue focusing on the orthopedic surgical robot business and increase investment in new technologies and products[23]. - The company is actively pursuing international certification for its products, aiming to enhance its market presence globally[72]. - The company is exploring partnerships with key industry players to enhance its competitive edge and drive growth[144]. - A strategic acquisition is in the pipeline, aimed at enhancing the company's technological capabilities and expanding its product portfolio[144]. - The company is focused on building a marketing system that integrates equipment sales, consumable sales, and operational services for orthopedic robots[131]. Environmental and Social Responsibility - The company emphasizes ESG management, focusing on environmental protection and sustainable operations[179]. - The company is not classified as a key pollutant discharge unit and has not faced any administrative penalties for environmental issues during the reporting period[181]. - The company actively implements energy-saving measures and promotes the use of electric vehicles for administrative purposes to reduce carbon emissions[187]. - The company donated 300,000 yuan to the Hainan Shanglin Sunshine Medical Development Foundation in 2022[189].